» Articles » PMID: 18494814

Gene Targeting to the Stroma of the Prostate and Bone

Overview
Journal Differentiation
Publisher Elsevier
Date 2008 May 23
PMID 18494814
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Stromal-epithelial interactions mediated by paracrine signaling mechanisms dictate prostate development and progression of prostate cancer. The regulatory role of androgens in both the prostate stromal and epithelial compartments set the prostate apart from many other organs and tissues with regard to gene targeting. The identification of androgen-dependent prostate epithelial promoters has allowed successful gene targeting to the prostate epithelial compartment. Currently, there are no transgenic mouse models available to specifically alter gene expression within the prostate stromal compartment. As a primary metastatic site for prostate cancer is bone, the functional dissection of the bone stromal compartment is important for understanding stromal-epithelial interactions associated with metastatic tumor growth. Use of currently available methodologies for the expression or deletion of gene expression in recent research studies has advanced our understanding of the stroma. However, the complexity of stromal heterogeneity within the prostate remains a challenge to obtaining compartment or cell-lineage-specific in vivo models necessary for furthering our understanding of prostatic developmental, benign, tumorigenic, and metastatic growth.

Citing Articles

Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity.

Jia D, Zhou Z, Kwon O, Zhang L, Wei X, Zhang Y Nat Commun. 2022; 13(1):6828.

PMID: 36369237 PMC: 9652358. DOI: 10.1038/s41467-022-34665-z.


Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats.

Suzuki S, Naiki-Ito A, Kuno T, Punfa W, Long N, Kato H J Toxicol Pathol. 2015; 28(1):21-6.

PMID: 26023257 PMC: 4337495. DOI: 10.1293/tox.2014-0050.


Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.

Jackson 2nd R, Placzek W, Fernandez A, Ziaee S, Chu C, Wei J Neoplasia. 2012; 14(7):656-65.

PMID: 22904682 PMC: 3421961. DOI: 10.1593/neo.12640.


Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts.

Yu S, Yeh C, Niu Y, Chang H, Tsai Y, Moses H Prostate. 2011; 72(4):437-49.

PMID: 21739465 PMC: 4402036. DOI: 10.1002/pros.21445.


Role for stromal heterogeneity in prostate tumorigenesis.

Kiskowski M, Jackson 2nd R, Banerjee J, Li X, Kang M, Iturregui J Cancer Res. 2011; 71(10):3459-70.

PMID: 21444670 PMC: 3096737. DOI: 10.1158/0008-5472.CAN-10-2999.


References
1.
Dong J . Prevalent mutations in prostate cancer. J Cell Biochem. 2005; 97(3):433-47. DOI: 10.1002/jcb.20696. View

2.
Ao M, Williams K, Bhowmick N, Hayward S . Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res. 2006; 66(16):8007-16. PMC: 4067141. DOI: 10.1158/0008-5472.CAN-05-4451. View

3.
Patsch C, Edenhofer F . Conditional mutagenesis by cell-permeable proteins: potential, limitations and prospects. Handb Exp Pharmacol. 2007; (178):203-32. DOI: 10.1007/978-3-540-35109-2_9. View

4.
Sugimura Y, Cunha G, Bigsby R . Androgenic induction of DNA synthesis in prostatic glands induced in the urothelium of testicular feminized (Tfm/Y) mice. Prostate. 1986; 9(3):217-25. DOI: 10.1002/pros.2990090302. View

5.
Donjacour A, Cunha G . Stromal regulation of epithelial function. Cancer Treat Res. 1991; 53:335-64. DOI: 10.1007/978-1-4615-3940-7_16. View